Human Papillomavirus – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of human papillomavirus (HPV) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of HPV for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s HPV forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with HPV?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HPV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology forecasts two HPV patient populations, as follows:
- Total prevalent cases by high-risk HPV.
- HPV high-risk genotype proportions.
Note: Coverage may vary by country.
Table of contents
- Human Papillomavirus - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Total Prevalence of Human Papillomavirus per 100 Adults in 2021 and 2041
- Total Prevalence of Human Papillomavirus per 100 Adults in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Human Papillomavirus Over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Human Papillomavirus Over the Next 20 Years
- Number of Additional Total Prevalent Cases of Human Papillomavirus Avoided Over 2021-2041 in the Countries Under Study
- Number of Additional Total Prevalent Cases of Human Papillomavirus Avoided Over 2021-2041 in the Countries Under Study
- Proportion of High-Risk Human Papillomavirus Genotypes Among Total High-Risk Human Papillomavirus Strains
- Proportion of High-Risk Human Papillomavirus Genotypes Among Total High-Risk Human Papillomavirus Strains
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.